Abstract:

The expected growth of the elderly population at highest risk for Parkinson’s disease (PD) in the next decades makes the identification of factors that promote or prevent the disease an important goal. In addition, new therapies - aiming to delay the progression of PD are also needed. However, there have been few clinical trials designed to investigate neuroprotection. Thus the application of an appropriate in vitro model such as the neuroblastoma SH-SY5Y cell line is extremely helpful. These cells were selected due to its human origin, catecholaminergic neuronal properties, and ease of maintenance.